Single Cell Technology and AB Biosciences have entered a collaboration to identify therapeutic antibodies.
SCT will utilize its patented platform to massively screen plasma cells, measure the kinetics of secreted antibodies, and sequence the cognate light and heavy chain mRNA powered by next generation sequencing.
AB will select antibody targets, engineer protein antigens, and develop analytical tools to further characterize the large panel of antibodies identified by SCT's platform.
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity